FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4284671117> ?p ?o ?g. }

• W4284671117 endingPage "123363" @default.
• W4284671117 startingPage "123363" @default.
• W4284671117 abstract "A fully validated, simple, rapid and reproducible liquid chromatography-tandem mass spectrometry method was developed to determine NHC (N-hydroxycytidine), the active metabolite of Molnupiravir (MOL) in human plasma; one of the limited treatment options for SARS-CoV-2 in plasma of healthy volunteers. The internal standard (IS) used was ribavirin. The extraction of analyte and IS from plasma was performed using acetonitrile as a solvent for protein precipitation. Agilent Zorbax Eclipse plus C18, 4.6 × 150 mm, (5 µm) was used for chromatographic separation using a mixture of methanol0.2 % acetic acid (5:95, v/v) as a mobile phase that was pumped at a flow rate of 0.9 mL/min. Detection was performed on a triple quadrupole mass spectrometer operating in multiple reaction monitoring (MRM) employing positive ESI interface using API4500 triple quadrupole tandem mass spectrometer system, with the transitions set at m/z 260.10 → 128.10 and 245.10 → 113.20 for NHC and IS respectively. Method validation was performed in accordance with United States FDA bioanalytical guidance. The concentration range of 20.0-10000.0 ng/mL was used to establish linearity via weighted linear regression approach (1/x2). Moreover, the analyzed pharmacokinetic data from twelve Egyptian healthy volunteers were used to develop a population pharmacokinetic model for NHC. The developed model was used to perform simulations and evaluate the current MOL dosing recommendations through calculating the maximum concentration (Cmax) the safety metric and area under the curve (AUC0-12 h) the efficacy metric for 1000 virtual subjects. Geometric mean ratios (GMR) with their associated 90% confidence intervals (CI) compared to literature values were computed. Geometric means of simulation-based Cmax and AUC0-12 were 3827 ng/mL (GMR = 1.05; 90% CI = 0.96-1.15) and 9320 ng.h/mL (GMR = 1.04; 90% CI = 0.97-1.11), respectively indicating that current MOL dosage can achieve the therapeutic targets and dose adjustment may not be required for the Egyptian population. The developed model could be used in the future to refine MOL dosage once further therapeutic targets are identified." @default.
• W4284671117 created "2022-07-08" @default.
• W4284671117 creator A5003678491 @default.
• W4284671117 creator A5005841144 @default.
• W4284671117 creator A5014390159 @default.
• W4284671117 creator A5026385722 @default.
• W4284671117 creator A5043057371 @default.
• W4284671117 creator A5063077363 @default.
• W4284671117 creator A5068328938 @default.
• W4284671117 creator A5070809928 @default.
• W4284671117 creator A5001501036 @default.
• W4284671117 date "2022-08-01" @default.
• W4284671117 modified "2023-09-30" @default.
• W4284671117 title "A validated LC-MS/MS method for determination of antiviral prodrug molnupiravir in human plasma and its application for a pharmacokinetic modeling study in healthy Egyptian volunteers" @default.
• W4284671117 cites W105671925 @default.
• W4284671117 cites W2008832693 @default.
• W4284671117 cites W2035387023 @default.
• W4284671117 cites W2080843536 @default.
• W4284671117 cites W2142810912 @default.
• W4284671117 cites W2793680220 @default.
• W4284671117 cites W2883070661 @default.
• W4284671117 cites W3005291354 @default.
• W4284671117 cites W3111269760 @default.
• W4284671117 cites W3132800081 @default.
• W4284671117 cites W3135540980 @default.
• W4284671117 cites W3152320732 @default.
• W4284671117 cites W3198019853 @default.
• W4284671117 cites W3198844580 @default.
• W4284671117 cites W3204448507 @default.
• W4284671117 cites W3207216740 @default.
• W4284671117 cites W4200051875 @default.
• W4284671117 doi "https://doi.org/10.1016/j.jchromb.2022.123363" @default.
• W4284671117 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35810537" @default.
• W4284671117 hasPublicationYear "2022" @default.
• W4284671117 type Work @default.
• W4284671117 citedByCount "13" @default.
• W4284671117 countsByYear W42846711172023 @default.
• W4284671117 crossrefType "journal-article" @default.
• W4284671117 hasAuthorship W4284671117A5001501036 @default.
• W4284671117 hasAuthorship W4284671117A5003678491 @default.
• W4284671117 hasAuthorship W4284671117A5005841144 @default.
• W4284671117 hasAuthorship W4284671117A5014390159 @default.
• W4284671117 hasAuthorship W4284671117A5026385722 @default.
• W4284671117 hasAuthorship W4284671117A5043057371 @default.
• W4284671117 hasAuthorship W4284671117A5063077363 @default.
• W4284671117 hasAuthorship W4284671117A5068328938 @default.
• W4284671117 hasAuthorship W4284671117A5070809928 @default.
• W4284671117 hasBestOaLocation W42846711171 @default.
• W4284671117 hasConcept C10390740 @default.
• W4284671117 hasConcept C112705442 @default.
• W4284671117 hasConcept C113196181 @default.
• W4284671117 hasConcept C137535248 @default.
• W4284671117 hasConcept C149151106 @default.
• W4284671117 hasConcept C162356407 @default.
• W4284671117 hasConcept C172493649 @default.
• W4284671117 hasConcept C185592680 @default.
• W4284671117 hasConcept C22979827 @default.
• W4284671117 hasConcept C2777477808 @default.
• W4284671117 hasConcept C31827203 @default.
• W4284671117 hasConcept C43617362 @default.
• W4284671117 hasConcept C55493867 @default.
• W4284671117 hasConcept C71043704 @default.
• W4284671117 hasConcept C71924100 @default.
• W4284671117 hasConcept C74774607 @default.
• W4284671117 hasConcept C98274493 @default.
• W4284671117 hasConceptScore W4284671117C10390740 @default.
• W4284671117 hasConceptScore W4284671117C112705442 @default.
• W4284671117 hasConceptScore W4284671117C113196181 @default.
• W4284671117 hasConceptScore W4284671117C137535248 @default.
• W4284671117 hasConceptScore W4284671117C149151106 @default.
• W4284671117 hasConceptScore W4284671117C162356407 @default.
• W4284671117 hasConceptScore W4284671117C172493649 @default.
• W4284671117 hasConceptScore W4284671117C185592680 @default.
• W4284671117 hasConceptScore W4284671117C22979827 @default.
• W4284671117 hasConceptScore W4284671117C2777477808 @default.
• W4284671117 hasConceptScore W4284671117C31827203 @default.
• W4284671117 hasConceptScore W4284671117C43617362 @default.
• W4284671117 hasConceptScore W4284671117C55493867 @default.
• W4284671117 hasConceptScore W4284671117C71043704 @default.
• W4284671117 hasConceptScore W4284671117C71924100 @default.
• W4284671117 hasConceptScore W4284671117C74774607 @default.
• W4284671117 hasConceptScore W4284671117C98274493 @default.
• W4284671117 hasLocation W42846711171 @default.
• W4284671117 hasLocation W42846711172 @default.
• W4284671117 hasLocation W42846711173 @default.
• W4284671117 hasOpenAccess W4284671117 @default.
• W4284671117 hasPrimaryLocation W42846711171 @default.
• W4284671117 hasRelatedWork W1964236216 @default.
• W4284671117 hasRelatedWork W1981874357 @default.
• W4284671117 hasRelatedWork W2018070089 @default.
• W4284671117 hasRelatedWork W2047996374 @default.
• W4284671117 hasRelatedWork W2058346847 @default.
• W4284671117 hasRelatedWork W2114487470 @default.
• W4284671117 hasRelatedWork W3023432142 @default.
• W4284671117 hasRelatedWork W3028635380 @default.
• W4284671117 hasRelatedWork W3046410380 @default.
• W4284671117 hasRelatedWork W3202482790 @default.
• W4284671117 hasVolume "1206" @default.

• next